Isofol Announces Presentation on the Global Phase 3 Study of arfolitixorin in Metastatic Colorectal Cancer at 2019 ESMO Congress GOTHENBURG,…
Isofol Announces that an Abstract has been Accepted for Presentation at the 2019 ESMO Congress GOTHENBURG, Sweden, September 12, 2019…
Isofol Announces Management Team Evolution with Appointment of Dr. Roger Tell as Chief Medical Officer GOTHENBURG, Sweden, August 15, 2019…
Isofol Receives Clinical Use Patent Approval in the United States for Drug Candidate arfolitixorin GOTHENBURG, Sweden, June 25, 2019 –…
Isofol Announces Election of Three New Board Members GOTHENBURG, Sweden, June 10, 2019 – Isofol Medical AB (publ) (Nasdaq First…
Isofol’s drug candidate arfolitixorin receives clinical patent approval in the United States GOTHENBURG, Sweden, May 21, 2019 – Isofol Medical…
Isofol Reports 58 % Overall Response Rate in Patients with Metastatic Colorectal Cancer in Phase 1/2a Open Label Extension Study…
GOTHENBURG, Sweden, February 1, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced that all senior…
GOTHENBURG, Sweden, January 17, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced positive results from…
GOTHENBURG, Sweden, December 18, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced that the first…
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.